Edition:
United States

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

58.35EUR
29 Jul 2016
Change (% chg)

€-1.09 (-1.83%)
Prev Close
€59.44
Open
€59.50
Day's High
€59.50
Day's Low
€57.75
Volume
149,856
Avg. Vol
85,419
52-wk High
€63.05
52-wk Low
€45.31

IPN.PA

Chart for IPN.PA

About

Ipsen SA is a France-based pharmaceutical company that produces a range of various types of drugs. Its portfolio includes pharmaceutical products divided into four targeted therapeutic areas: Neurology, Endocrinology, Uro-Oncology and Primary Care. In the Neurology segment the Company offers a product called Dysport, in... (more)

Overall

Beta: 0.44
Market Cap(Mil.): €4,862.87
Shares Outstanding(Mil.): 83.34
Dividend: 0.85
Yield (%): 1.46

Financials

  IPN.PA Industry Sector
P/E (TTM): 20.68 38.77 39.28
EPS (TTM): 2.82 -- --
ROI: 14.45 15.17 14.40
ROE: 19.51 16.12 15.47

BRIEF-Supplemental application filed for Ipsen's Somatuline in Japan

* Says its Janapese partner Teijin Pharma has filed a supplemental application with Pharmaceuticals and Medical Devices Agency to use Ipsen's subcutaneous drug Somatuline (lanreotide) for the treatment of neuroendocrine tumors (NETs) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 28 2016

UPDATE 1-Ipsen shares jump after raised guidance for specialty care

PARIS, July 28 Shares of French drugmaker Ipsen are up more than 6 percent on Thursday after the company said it had raised its full-year guidance for specialty care sales growth on the back of first half results.

Jul 28 2016

BRIEF-Ipsen and Exelixis receive positive CHMP opinion for Cabometyx

* Ipsen and its partner Exelixis receive positive CHMP opinion for Cabometyx (cabozantinib) for treatment of advanced renal cell carcinoma in adults

Jul 22 2016

BRIEF-Ipsen SA says David Meek appointed as CEO

* Marc De Garidel will assume role of non-executive chairman and will continue to serve board of directors

Jul 11 2016

BRIEF-Ipsen SA issues inaugural EUR300 mln 7-year notes

* Ipsen successfully issues inaugural eur300 million 7-year notes

Jun 09 2016

BRIEF- Ipsen Biopharmaceuticals announces publication on Somatuline Depot

* Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, announced on Saturday that Endocrine Practice has published Phase III clinical trial results examining the efficacy and safety of Somatuline Depot (lanreotide) Injection 120 mg in patients with carcinoid syndrome

Jun 06 2016

BRIEF-Ipsen and Oncodesign enter into a strategic oncology partnership

* Oncodesign and Ipsen enter into a strategic partnership in oncology

May 03 2016

BRIEF-Ipsen and Oncodesign enter into a strategic oncology partnership

* Oncodesign and Ipsen enter into a strategic partnership in oncology

May 03 2016

BRIEF-Ipsen Q1 sales rise 3.4% to 362.0 million euros

* Q1 sales EUR 362.0 million ($410.29 million) versus EUR 350.1 million year ago

Apr 28 2016

BRIEF-Ipsen partner Exelixis obtains FDA approval of CABOMETYX tablets

* Announces that its partner Exelixis obtained FDA approval of CABOMETYX (cabozantinib) tablets for patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 26 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Pechala's Reports
$25.00
Provider : Sadif Analytics Prime
$10.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.